Public Company News

CTK Launches Dedicated OTC Facility in California, Establishing a Strategic Hub for Global K-beauty Expansion

SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- CTK(KOSDAQ: 260930), a global K-beauty original design manufacturer (ODM) for cosmetics, has begun operations at CTK OTC LABORATORIES (COL), its new dedicated over-the-counter (OTC) manufacturing facility inCorona, California.

2025-12-08 21:30 2217

TOYO Co., Ltd. Acquires Remaining 24.99% Interest in TOYO Solar LLC

TOKYO, Dec. 8, 2025 /PRNewswire/ -- TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF),  ("TOYO" or the "Company"), a solar solution company, today announced that it has acquired the remaining 24.99% membership interest in its U.S. subsidiary, TOYO Solar LLC, making it a whol...

2025-12-08 21:30 3388

Locksley Announces Oversubscribed A$17 Million Placement Lead by U.S. Investors Funding to Accelerate Execution of Locksley's U.S. Mine to Market Strategy

SAN BERNARDINO, Calif., Dec. 8, 2025 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY/OTCQX: LKYRF/ADR: LKYLY) announced the successful completion of a heavily oversubscribed capital raising, securing firm commitments to raise approximatelyA$17 million via a placement of new shares at A$0.24 ...

2025-12-08 21:30 4433

Hyundai Mobis Establishes Additional SW R&D Hub in Bengaluru, India

* Following the establishment of the integrated R&D center in Hyderabad earlier this year, the company is cultivating a locally self-contained SW hub in the IT-centric city of Bengaluru * Securing additional top-tier local software talent to enhance the role of its Indian R&D center… Opening ...

2025-12-08 21:00 3009

Autocrypt Announces Product Release of Post-Quantum PKI Product, Pioneering PQC-enabled Solutions for Automotive OEMs

SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Leading automotive cybersecurity solutions provider AUTOCRYPT announced onDecember 8, 2025, the launch of "AutoCrypt PKI-Vehicles," a new next-generation Public Key Infrastructure (PKI) solution supporting ML-DSA, a post-quantum digital signature ...

2025-12-08 21:00 3618

HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025

Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage b...

2025-12-08 20:00 4847

51Talk Online Education Group Announces New Share Repurchase Program

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, today announced that its board of directors has authorized a new share repurchase program under whi...

2025-12-08 19:35 4076

Huya Announces January 7, 2026 Open Beta Launch for Goose Goose Duck Mobile in Chinese Mainland

GUANGZHOU, China, Dec. 8, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that the popular social deduction gameGoose Goose Duck mobile, co‑published by Huya and Kingsoft Shiyou in the Chinese mainl...

2025-12-08 19:30 3049

51Talk Online Education Group Announces Third Quarter 2025 Results

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter endedSeptember 30, 2025. Third Quarter 2025 F...

2025-12-08 19:30 5796

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...

2025-12-08 14:36 3022

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...

2025-12-08 10:08 5106

Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation o...

2025-12-08 10:00 4511

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2025-12-08 09:02 2615

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...

2025-12-08 08:15 4291

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtage...

2025-12-07 17:21 4836

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released byChina's National Healthcare Securi...

2025-12-07 14:18 2956

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-12-07 11:40 3698

SK hynix Honored with Two Major Titles at GSA Awards 2025

* Company named "Best Financially Managed Semiconductor Company (Achieving Greater than$1 Billion in Annual Sales)" and "Outstanding Asia-Pacific Semiconductor Company" simultaneously * Accelerates recovery from market downturn leveraging world-class HBM leadership; Global management performa...

2025-12-07 07:48 3572

Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'

* Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments * Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session ...

2025-12-05 22:00 6640

PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("the Company"), listed on Nasdaq, today announced its financial results for the six months endedSeptember 30, 2025, achieving substantial revenue increase and a meaningful improvement in gross profit following its ...

2025-12-05 21:45 6790
1 ... 129130131132133134135 ... 744